Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125667871 | 12566787 | 1 | I | 20160711 | 20160718 | 20160718 | EXP | US-TEVA-677269USA | TEVA | SEITER K, AHMED N, SHAIKH A, BASKIND P, LIU D. CLAG-BASED INDUCTION THERAPY IN PREVIOUSLY UNTREATED HIGH RISK ACUTE MYELOID LEUKEMIA PATIENTS. LEUK-RES 2016;46:74-78. | 65.00 | YR | F | Y | 0.00000 | 20160718 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125667871 | 12566787 | 1 | PS | IDARUBICIN | IDARUBICIN | 1 | Unknown | 12 MG/M2 TIMES 3 DAYS, 1 CYCLE | U | 65036 | |||||||||
125667871 | 12566787 | 2 | SS | CLADRIBINE. | CLADRIBINE | 1 | Unknown | 5 MG/M2 OVER 2 HOUR; TOTAL 1 CYCLE | U | 0 | |||||||||
125667871 | 12566787 | 3 | SS | CYTARABINE. | CYTARABINE | 1 | Unknown | U | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125667871 | 12566787 | 2 | Acute myeloid leukaemia |
125667871 | 12566787 | 3 | Acute myeloid leukaemia |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125667871 | 12566787 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125667871 | 12566787 | Pancytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |